RemSleep Holdings (RMSL) Net Cash Flow Growth (1y) (2012 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | RemSleep Holdings | - | - | -7,636.00 | -81.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -81.35% |
| Sep 30, 2025 | 20.25% |
| Jun 30, 2025 | -186.14% |
| Mar 31, 2025 | 280.95% |
| Dec 31, 2024 | 61.48% |
| Sep 30, 2024 | 49.23% |
| Jun 30, 2024 | 91.66% |
| Mar 31, 2024 | 103.06% |
| Dec 31, 2023 | 41.92% |
| Sep 30, 2023 | 23.46% |
| Jun 30, 2023 | 76.41% |
| Mar 31, 2023 | -159.78% |
| Dec 31, 2022 | -131.28% |
| Sep 30, 2022 | -111.55% |
| Jun 30, 2022 | -944.29% |
| Mar 31, 2022 | 1,313.36% |
| Dec 31, 2021 | 5,763.61% |
| Sep 30, 2021 | 4,000.07% |
| Jun 30, 2021 | 193.25% |
| Mar 31, 2021 | -66.71% |
| Dec 31, 2020 | -2.78% |
| Sep 30, 2020 | 161.31% |
| Jun 30, 2020 | -249.86% |
| Mar 31, 2020 | 383.88% |
| Dec 31, 2019 | 173.56% |
| Sep 30, 2019 | -298.20% |
| Jun 30, 2019 | 365.74% |
| Mar 31, 2019 | -44.85% |
| Dec 31, 2018 | -1,341.19% |
| Sep 30, 2018 | 1,222.49% |
| Jun 30, 2018 | -1,623.60% |
| Sep 30, 2017 | 25,558.33% |
| Jun 30, 2017 | -5,163.16% |
| Dec 31, 2015 | -198.75% |
| Dec 31, 2014 | 7,284.62% |
| Dec 31, 2013 | 100.13% |
| Sep 30, 2013 | -100.00% |
| Jun 30, 2013 | 94.57% |
| Mar 31, 2013 | 108.76% |
| Dec 31, 2012 | -119.14% |
| Sep 30, 2012 | 35,140.52% |